• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2025-2026
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
  • About
    • GDPR
  • Contact

CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

January 28, 2020 By admin Leave a Comment

MONMOUTH JUNCTION, N.J., Jan. 28, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the recent publication in The Lancet entitled, “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.” The article notes the correlation of high levels of circulating inflammatory cytokines, or “cytokine storm”, with severity of illness in patients infected with the Wuhan coronavirus (2019-nCoV). These data provide the rationale to potentially use CytoSorb, the first specifically-approved extracorporeal cytokine adsorber in the European Union, in this setting. CytoSorb is distributed in 58 countries worldwide, and is available in Hong Kong, Vietnam, Malaysia, France, and Australia where patients infected with the virus have been reported.

In this publication, Huang, et al. describe the characteristics and clinical course of hospitalized patients infected with the Wuhan coronavirus who did, or did not, require treatment in the intensive care unit (ICU). Those that were admitted to the ICU, particularly those with severe disease, exhibited significantly higher levels of inflammatory cytokines compared to those that did not. This “cytokine storm” can trigger a viral sepsis in coronavirus infection, where viral replication and excessive, uncontrolled systemic inflammation can lead to pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, secondary bacterial pneumonia, and potentially death. This same correlation between cytokine storm and severity of illness was observed previously in both SARS and MERS patients.

Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, “CytoSorb has been used to control deadly inflammation in tens of thousands of treatments in patients with either bacterial or viral sepsis. Although CytoSorb has not yet been specifically used to treat patients infected with this newly emergent coronavirus, we believe it can play an important role, with or without anti-viral therapies, in the treatment of this highly inflammatory illness.”

The Wuhan coronavirus has a relatively asymptomatic incubation period for up to 14 days, often marked only by dry cough and fatigue, when the afflicted can transmit the virus to others, followed by fever and the development of viral pneumonia. The spread of the coronavirus has also been facilitated by international travel.

Researchers in Hong Kong have warned that the number of people infected by the Wuhan coronavirus (2019-nCoV) could be 30 times more than the reported 4,500 cases that have killed 106 people already, with now 5 confirmed cases and more than 100 suspected cases in the U.S. The contagiousness, lack of specific treatments or vaccines, and feared mortality has created a health scare in China and in many countries around the world similar to the 2002-2003 SARS (Severe Acute Respiratory Syndrome) coronavirus outbreak in China that infected 8,098 people and killed 774 (or 1 in 10 died), and the 2012 MERS (Middle East Respiratory Syndrome) coronavirus contagion with 2,494 confirmed cases and 858 deaths to date (approximately 1 in 3 died).

Source: CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorbents is conducting its pivotal REFRESH 2-AKI trial – a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury. The Company has also initiated the company-sponsored U.K. TISORB trial evaluating the removal of ticagrelor in emergency cardiac surgery patients. CytoSorb® has been used in more than 80,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others. For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com

Filed Under: Tech Tagged With: Coronavirus, cytokine storm

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Unlocking Critical Minerals: USGS Invites States to Turn Mine Waste into Treasure
  • Blacksmith Reimagines Continuous Integration with AI-Optimized Infrastructure
  • Cloudflare Acquires Outerbase and Expands AI Agent Capabilities to Transform Developer Experiences
  • Cloudflare’s Web Application Firewall Earns Leader Recognition in Forrester Wave Q1 2025
  • Kioxia Unveils Groundbreaking 122.88 TB SSD for Advanced AI and Cloud Workloads
  • Linux Foundation and OpenInfra Foundation Unite to Drive Cloud Native Innovation
  • Decoding China’s Tech Narratives and the Reality Behind Them
  • Turing Raises $111 Million to Propel AGI Innovation and Real-World AI Deployment
  • Apple Unveils the All-New MacBook Air with M4 Chip
  • Apple Unveils the New Mac Studio: A Powerhouse for Professionals and AI

Media Partners

  • Market Analysis
  • Cybersecurity Market
China’s Strategic Shift to RISC-V: Market Implications and Growth Prospects
Understanding Transfer Pricing: A Key Component of Multinational Business Operations
A Comprehensive Tour of Project Management Tools and Integration Platforms
Implementing Odoo ERP in a Small Manufacturing Enterprise: Costs and Considerations
Economic Optimism Meets Uncertainty: Blue Chip Indicators Highlight Post-Election Fiscal Concerns and AI’s Looming Impact
The Future of Connectivity: Insights from Ericsson’s November 2024 Mobility Report
Platinum Market Faces Sustained Deficit Amidst Strong Demand and Constrained Supply
Breaking Beijing’s Grip: U.S. and Australia Unite Against China’s Rare Earth Monopoly
Global AI-Powered Accounting and Audit Services Market Analysis 2023-2030: Growth, Trends, and Forecast
The Re-Emergence of PHP
INE Security Alert: Top 5 Takeaways from RSAC 2025
Cloudflare Starts 2025 Strong with Record-Breaking Deals and Steady Financial Growth
Lydsec Digital Technology Sets Course for Growth with Emerging Stock Market Debut
Doppel Secures $35M in Series B Funding, Accelerating AI-Driven Social Engineering Defense
CHAOS Industries Secures $275 Million to Advance Next-Generation Defense Systems
University of California, Irvine Triumphs at 2025 National Collegiate Cyber Defense Championship
Terra Security Wins AWS, CrowdStrike, and NVIDIA Cybersecurity Startup Accelerator 2025
Link11 brings three brands together on one platform with new branding
SecAI Debuts at RSA 2025, Redefining Threat Investigation with AI
Veza Secures $108 Million in Series D Funding to Redefine Identity Security

Media Partners

  • Market Research Media
  • Technology Conferences
The Rise of Headless Content Frameworks in Distributed Media Projects
Developing Web Projects: From Concept to Launch
The Rise of APS-C Cameras: A Professional Renaissance in Photography
Market Brief: Disruption in Spanish Orange Supply Chain and Strategic Response by UK Retailers
Global AI-Powered Movie Scenario Market Analysis 2023-2030: Growth, Trends, and Forecast
Market Research Report: US Government Cybersecurity Market in 2024
Market Research Report: Global Advertising Revenue Projections and Trends in the Entertainment & Media Industry
Social Media: The Rise of Formulaic Content
Netflix’s Creative Decline: The Rise of Formulaic Content
The Transformation of Media: Navigating the Waning Allure of Social Platforms
Apple Announces WWDC25, June 9 to 13, 2025
Adobe Summit 2025, March 17-20, Las Vegas
Embedded World 2025, from 11 to 13 March 2025 in Nuremberg
SATELLITE 2025: Uniting the Global Satellite and Space Communities
The milestone 10th edition of Chatbot Summit on March 31 – April 1, 2025, The Ritz-Carlton, Berlin
Snowflake Summit 2025, scheduled for June 2-5, 2025, in San Francisco
The NVIDIA GPU Technology Conference (GTC) 2025 is set to take place from March 17 to 21 at the San Jose McEnery Convention Center in San Jose, California
The Taipei Nangang Exhibition Center is set to host COMPUTEX 2025 from May 20 to May 23
The Mobile World Congress (MWC 2025) will kick off from March 3 to 6 in Barcelona, Spain
IOT Solutions World Congress 2025: Forging the Future of Industrial Innovation

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains